Aug. 23, 2024 — Qure.ai recently announced its AI-powered chest CT solution, qCT LN Quant, has received 510(k) FDA clearance. The new AI solution is now available to support radiologists and pulmonologists in analyzing lung nodules on non-contrast chest CT scans and tracking volumetric growth as part of progression monitoring.
qCT LN Quant joins the Qure.ai US AI-powered Lung Cancer care continuum, featuring end-to-end AI solutions to identify, measure, manage, and monitor lung health. This includes ‘qXR LN’ for the early detection and localization of lung nodules on chest X-rays to support early lung cancer detection beyond traditional CT-based screening initiatives, and ‘qTrack,’ a multi-modality lung nodule management platform that integrates with Electronic Medical Records (EMRs) to help find, report, collaborate, and prioritize lung cancer patient cases.
qCT LN Quant offers advanced quantitative characterization of solid lung nodules, measuring average, short-axis, long-axis, and effective diameters. It allows clinicians to analyze morphological data across single or multiple thoracic studies, including estimated volume doubling time and tracking of nodules over several time points. Furthermore, it generates detailed 2D and 3D reconstructions, Brock malignancy risk scores, and Fleischner Society guidelines-based management suggestions to support consistent and reliable clinical decision-making. qCT LN Quant is potentially eligible under two CPT codes for reimbursement – tissue quantification CPT 0722T for CT and 3D reconstruction code.
For more information, please visit www.qure.ai/.
March 26, 2026 
